0001104659-24-005247.txt : 20240119
0001104659-24-005247.hdr.sgml : 20240119
20240119163425
ACCESSION NUMBER: 0001104659-24-005247
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240117
FILED AS OF DATE: 20240119
DATE AS OF CHANGE: 20240119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Swartz Robin
CENTRAL INDEX KEY: 0001909636
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 24546064
MAIL ADDRESS:
STREET 1: C/O VOYAGER THERAPEUTICS, INC.
STREET 2: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 75 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
tm243664-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-17
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001909636
Swartz Robin
C/O VOYAGER THERAPEUTICS, INC.,
75 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer
0
Common Stock
2024-01-17
4
S
0
2543
7.15
D
72327
D
Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2024. The sales do not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.27, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Includes 3,253 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.
/s/ Scott MacDonald, as Attorney-in-Fact for Robin Swartz
2024-01-19